Open Access Open Access  Restricted Access Subscription or Fee Access

Pharmacology of Migrain

Patil Nikita Kantilal, Patil Sayali Dinesh, Patil Lalit Radheshyam, Azam Z. Shaikh, Rajesh D. Ahire, S.P. Pawar


Migraine is too an explosive headache that influence nearly 10% of grown person on all sides. The society migraine is an ordinary cerebral sickness identify with a repeated headache frequently go along with by vomiting, phonophobia and nausea. Migraine impact an evaluate more than 10% of human beings pandemic, occurs most of ten included in human beingaged 20 to 50 years& it about a times -day to day in female more than in male. According to clinical and epidemiology studies there are number of factor which precipitate the risk of migrant attack. Prevention of migraine includes both Pharmacological and non- pharmacological action. Pharmacological action includes prevention with B-blockers, Calcium channel blockers; tricyclic antidepressants antiepileptic drugs are considered first line preventive treatment and in non-pharmacological included use of nutraceutical. In this article we focused on migraine and its pharmacology, prevention and treatment.


Migraine, substantianigra, Calcium channel blockers, pharmacological action, nutraceutical

Full Text:



Stovner Lj, Hagen K, Jensen R, et al. The global burdenoh headache: a documentation of headache prevelance and disability worldwide. cephalagia.2007;27:193-210.

Stam A.H, de vries B, Janssen sac, et al. shared genetic factor in migraine and depression. Evidence formsa genetic isolated. Neurology.2010;74(4):288-294.

Jet MI Afridi MI, Amar W, Lal Prevalence of migraine among patients of depressive disorder. Pak J Med Sci 2018;34(4):964-967.

T.J Steiner, A.J. Scher, W.F. Stewart. K. kolo deners, Liberman, & R. B. Lipton." The prevalence anddisability burden of adult migraine in England and their relationship to age gender & Ethnicity", cephalalgia, vol. 23, no. 7. pp 519-527, 2003.

CE Clarke. L. Macmillan, S. Sandhi & N.E.J wells, " Economic or Social impact of migraine”QJM- monthly Journal of the Association of physician, Vol. 89 no.1 pp. 77-84, 1996.

World Health Organization. Who fact sheet, 2016;1-2

World Health Organization, Neurologicaldisorder: a public health approach. neural disorder public Heal challenge ,2006;41-176.

Eadie M.J The photogenes is of migraine 17th of to Early 20th century understanding. J clinNeurosis: 2005; 12: 383-388.

Haut SR, Bigal ME, Lipton RB. chronic disorders with Episodic manifestation: focus on epilepsy and migraine Lancet Neurol 2006: 5: 148-151

Silberstein SD, Lipton RB, Slivinski m. classification of daily & near daily headache: findtrial of revised IHS criteria Neurology. 1996; 47: 871-875.

Kruit mc, van Buchem MA, Hofmann PA, et al. migraine as a risk factor for subclinical brain Lesion. JAMA 2004;291: 427-434.

Moskowitz MA, Cuter FM. SUMATRIPAN: A receptor targeted treatment for migraine. Ann Rev Med. 1993;145- 54

Burstein R, Magnitsky D, Goo - Aryeh I, Ranil BJ, Bajwa ZH. An association between migraine and Cutaneous allodynia. Ann Neurol. 2000; 47: 614-624.

Olesen J, Buskin R, Ashine M, Theft - Hansen P. origin of pain in migraine evidence for peripheral Sensitization Lancet neurol 2009; 8:679.90 [PubMed] [Google scholar]

Martin VT, Bhabhan MM. Toward a Rational Understanding of migraine Trigger factor medical clinics of North America – 2001; 85:911-941 [PubMed] [Google Scholar).

Lipton RB, Silberstein So, Stewart WF. AD update on the epidemiology of migraine. Headache: The journal of Head & face pain. 2005; 34: 319-328 [Google Scholar]

Scherr AI, Schwartz WF, Liberman, Lipton RB. prevalence of frequent Headache in a population Sample. Headache: The journal of Head & face pain 2003; 38:497-506 [[PubMed] [Google Scholar].

schwarz BS, Stewart WF, Simon D, Lipton RB Epidemiology of tension type Headache. JAMA the journal of the American medical Association 1998; 279 381- 383 [PubMed] [Google Scholar].

KempSF lackey RF Anaphylaxis: a Review of causes and mechanism. Journal of allergy& clinical immunology 20021; 110:341-348 [PubMed] [Google Scholar]

Martin PR How do Trigger Factor Acquire the capacity to precipitate Headache Behavior Research therapy 2001; 39:545 - 554 [PubMed [Google scholar]

Martin PR. Reece J. Forsyth M. Noise as a bragger For Headache: Relationship between exposures and Sensitivity Headache the journal of Head& face pain A 2006 46:962-972 [PubMed] [google Scholar].

Martin PPR, Leo L Reece J stress as a trigger for headache relationship between exposure and sensitivity. Anxiety, stress and coping 2007 20%/393-407 [PubMed] [google scholar

Giffin, NJ, Ruggiero, L, Lipton, RB. Premonitory symptoms in migraine: An electroni dairy study. Neurology 2003;60:935-940.

Wells RE, Bertsch SM, Buettner C, Phillips. RS, McCathyEP. Complementary and alternative medicine use among adults with migrainessevere headache.

welchKleeneSR, DAndera, SchultzReaper JA preliminary observation brain energy metabolismin migraine studies by in vivo phosphorous 31NMR spectroscopy. Neurology,1998;39(4)-538-41 CAS articles plumbed Google scholar

Borbioxoli B, Montagne P, Corelli P. Funicular R. Totti s Mon aril, ellal. Abnormal brain, and muscle energy metabolism shown by 31P magnetic resonance Spectroscopy in patients affected by migraine with aura. neurology 1992;42(6): 1209CAS Article PubMed Google Scholar.

Watanabe H, kilobars, T, on Kubo M, Tsuji s, Yuasa T- Elevation of cerebral lactate detected by localized IH- magnetic resonance Spectroscopy in migraine during the interictal period Neurology 1996;47(4): 1093-5.CAS Article PubMed Google Scholar

Schoene J, Jacquie, Leaner’s M. effectiveness of high-dose riboflavin in migraine prophylaxis A randomized convolved trial. neurology 1998; 50(2) 466 - 70 CAS Article PubMed Google Scholar.

MacLennanSC, wade FM, Forrest KM Ratnayake PO, Fagan E. Antony J High.dose riboflavin for migraine prophylaxis in children: a double-blind randomized placebo-controlled trial, Journal of child neurology 2008; 23(11):1300-4 Article PubMed Google Scholar

Athaliah Yo, Saing HB, Lolo A Riboflavin is migraine prophylaxis in adolescents. Pedalerindenol. 2012;52 ,1137, Article Google Scholar

Gaul-Diener HC, Dan eachU. Improvement of migraine symptoms with a proprietary Supplement Containing riboflavin, magnesium Q10: a randomized, placebo controlleddouble-blind, multicenter trial J Headache pain 2015;16- 516Article PubMed Google Scholar.

Di Lorenzo C pierhead F. Coppola G, Griego GS, Rengo C₁Cenedella Met al. mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs, Neurology 2009 ;72 (18) 1588-94. Article PubMed Google Scholar

Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979;2:326-8. [PMID: 89390]

Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G . Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:156-61. [PMID: 8062355]

Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia. 1984;4:107-11. [PMID: 6375873]

Havanka-Kanniainen Treatment of acute migraine attacks: ibuprofen and placebo compared. Headache1989;29:507-9[PMID:2676908]

Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992; 12:169-71; discussion 128. [PMID: 1623513]

Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, Eisner LS, et al. Aborting a migraine attack: naproxen sodium v ergotamine plus caffeine. Headache. 1988;28:263-6. [PMID: 3139584]

Johnson ES, Ratcliffe DM, Wilkinson M- Naproxen sodium in the treatment of migraine. Cephalalgia. 1985; 5:5-10. [PMID: 3886154]

Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia. 1984;4:253-63. [PMID: 6394143]

Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheitel F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998; 55:210-7. [PMID: 9482363]

Klassen A, Elkind A, Afghanabad M, Webster C, Laurena A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study. Group. Headache. 1997; 37:640-5. [PMID: 9439085]

Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology. 1997;49:1485-90. [PMID: 9409334]

Cutler NR, Cleghorn J, Samke JJ, Blo Pane Bianco D, Cheng H, et al. Pilot study MK -462 Help in migraine. Cephalalgia. 1996; 16:113-6. [PMID: 8665577]

Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol. 1996;53:1132-7. [PMID: 8912486

Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A , et al. . Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia. 1997;17:647-51. [PMID: 9350384]

Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998;38:281-7. [PMID: 9595867]

Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995;45:S5-9. [PMID: 7644082]

Myllylä VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache. 1998;38:201-7. [PMID: 9563211]

Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994;241:138-44. [PMID: 8164015]

Sumatriptan-an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group. Ear Neurol. 1991; 31:300-5. [PMID: 1653137]

Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. Eur Neurol. 1991;31:306-13. [PMID: 1653138]

Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. 1998;38:184-90. [PMID: 9563208]

Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F. High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. J Int Med Res. 1995;23:96-105. [PMID: 7601299]

Sargent J, Kirchner JR , Davis R , Kirkhart B . Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995;45:S10-4. [PMID: 7644079]

Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49:1210-8. [PMID: 9371896]

Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997;49:1219-25. [PMID: 9371897]

Visser WH, Klein KB, Cox RC, Jones D , Ferrari MD . 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology. 1996;46:522-6. [PMID: 8614525]

Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache. 1995;35:177-84. [PMID: 7775172]

Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol. 1996;53:1285-91. [PMID: 8970458]

Rohr J, Dufresne JJ. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia. 1985;5 Suppl 3 142-3.

Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia. 1987;7:131-3. [PMID: 3301001]

Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44:447-53. [PMID: 8145914]

Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-71. [PMID: 3519528]

Klapper J, Stanton J. The emergency treatment of acute migraine headache; a comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia. 1991;11 Suppl 11 159-60.

Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35:65-9. [PMID: 7737863]

Goldstein J, Gawel MJ, Winner P, et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache. 1998;38:516-22.

Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26:541-6. [PMID: 7486359]

Ellis GL, Delaney J, DeHart DA, Owens A . The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med. 1993;22:191-5. [PMID: 8427430]

Tek DS, McClellan DS, Olshaker JS , Allen CL , Arthur DC . A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19:1083-7. [PMID: 2221512]

Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double-blind, crossover trial. Headache. 1976;15:282-7. [PMID: 1107267]

Diamond S, Medina JL. Isometheptene—a non-ergot drug in the treatment of migraine. Headache. 1975;15:211-3. [PMID: 1100566]

Ryan RE. A study of midrin in the symptomatic relief of migraine headache. Headache. 1974;14:33-42. [PMID: 4599014]

Evers S. The efficacy of triptans in childhood and adolescence migraine. Curr Pain Headache Rep 2013; 17(7): 342.

Bonfert M, Straube A, Schroeder AS, et al. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics 2013; 44(1): 3–19.

Leinisch E, Evers S, Kaempfe N, et al. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study. Pain 2005; 117(3): 396–400

Lenaerts M, Bastings E, Sianard J, et al. Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. Acta Neurol Belg 1996; 96(2): 126–129

Leniger T, Pageler L, Stude P, et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005; 45(1): 42–46

Wood ME, Frazier JA, Nordeng HM, et al. Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity calibration to adjust for unmeasured confounding by migraine severity. Pharmacoepidemiol Drug Saf 2016; 25(5): 493–502.

O’Quinn S, Ephross SA, Williams V, et al. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263(1–2): 7–12

Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17(1): 1–7.

Fiore M, Shields KE, Santanello N, et al. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 2005; 25(9): 685–688.

Evans EW and Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42(4): 543–549

MacGregor EA, Victor TW, Hu X, et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, withinwoman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache 2010; 50(4): 528–538


  • There are currently no refbacks.

Copyright (c) 2022 Research & Reviews: A Journal of Pharmacology